JP2015531763A5 - - Google Patents

Download PDF

Info

Publication number
JP2015531763A5
JP2015531763A5 JP2015526987A JP2015526987A JP2015531763A5 JP 2015531763 A5 JP2015531763 A5 JP 2015531763A5 JP 2015526987 A JP2015526987 A JP 2015526987A JP 2015526987 A JP2015526987 A JP 2015526987A JP 2015531763 A5 JP2015531763 A5 JP 2015531763A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
braf
acceptable salt
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015526987A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015531763A (ja
JP6335169B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/067050 external-priority patent/WO2014027056A1/en
Publication of JP2015531763A publication Critical patent/JP2015531763A/ja
Publication of JP2015531763A5 publication Critical patent/JP2015531763A5/ja
Application granted granted Critical
Publication of JP6335169B2 publication Critical patent/JP6335169B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015526987A 2012-08-17 2013-08-15 コビメチニブ及びメベムラフェニブを投与することを含むメラノーマの併用療法 Active JP6335169B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201261684673P 2012-08-17 2012-08-17
US61/684,673 2012-08-17
US201261705575P 2012-09-25 2012-09-25
US61/705,575 2012-09-25
US201261706026P 2012-09-26 2012-09-26
US61/706,026 2012-09-26
US201261722725P 2012-11-05 2012-11-05
US61/722,725 2012-11-05
US201361780708P 2013-03-13 2013-03-13
US61/780,708 2013-03-13
PCT/EP2013/067050 WO2014027056A1 (en) 2012-08-17 2013-08-15 Combination therapies for melanoma comprising administering cobimetinib and vemurafinib

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017075880A Division JP2017160214A (ja) 2012-08-17 2017-04-06 コビメチニブ及びメベムラフェニブを投与することを含むメラノーマの併用療法

Publications (3)

Publication Number Publication Date
JP2015531763A JP2015531763A (ja) 2015-11-05
JP2015531763A5 true JP2015531763A5 (cg-RX-API-DMAC7.html) 2016-07-14
JP6335169B2 JP6335169B2 (ja) 2018-05-30

Family

ID=49035547

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015526987A Active JP6335169B2 (ja) 2012-08-17 2013-08-15 コビメチニブ及びメベムラフェニブを投与することを含むメラノーマの併用療法
JP2017075880A Pending JP2017160214A (ja) 2012-08-17 2017-04-06 コビメチニブ及びメベムラフェニブを投与することを含むメラノーマの併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017075880A Pending JP2017160214A (ja) 2012-08-17 2017-04-06 コビメチニブ及びメベムラフェニブを投与することを含むメラノーマの併用療法

Country Status (31)

Country Link
US (3) US11087354B2 (cg-RX-API-DMAC7.html)
EP (1) EP2884979B1 (cg-RX-API-DMAC7.html)
JP (2) JP6335169B2 (cg-RX-API-DMAC7.html)
KR (6) KR20240146112A (cg-RX-API-DMAC7.html)
CN (2) CN104640545A (cg-RX-API-DMAC7.html)
AU (1) AU2013304021B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015003418A2 (cg-RX-API-DMAC7.html)
CA (2) CA2928396A1 (cg-RX-API-DMAC7.html)
CL (1) CL2015000345A1 (cg-RX-API-DMAC7.html)
CO (1) CO7180225A2 (cg-RX-API-DMAC7.html)
DK (1) DK2884979T3 (cg-RX-API-DMAC7.html)
EA (1) EA033573B1 (cg-RX-API-DMAC7.html)
ES (1) ES2743427T3 (cg-RX-API-DMAC7.html)
HK (1) HK1206605A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20191533T1 (cg-RX-API-DMAC7.html)
HU (1) HUE044789T2 (cg-RX-API-DMAC7.html)
IL (1) IL237065B (cg-RX-API-DMAC7.html)
LT (1) LT2884979T (cg-RX-API-DMAC7.html)
MX (1) MX367970B (cg-RX-API-DMAC7.html)
MY (1) MY180613A (cg-RX-API-DMAC7.html)
NZ (1) NZ744862A (cg-RX-API-DMAC7.html)
PE (1) PE20151156A1 (cg-RX-API-DMAC7.html)
PH (1) PH12015500186A1 (cg-RX-API-DMAC7.html)
PL (1) PL2884979T3 (cg-RX-API-DMAC7.html)
PT (1) PT2884979T (cg-RX-API-DMAC7.html)
RS (1) RS59113B1 (cg-RX-API-DMAC7.html)
SG (3) SG10201708494QA (cg-RX-API-DMAC7.html)
SI (1) SI2884979T1 (cg-RX-API-DMAC7.html)
UA (1) UA114923C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014027056A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201500348B (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE044352T2 (hu) 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
DK2884979T3 (da) 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
WO2015095842A2 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
WO2015191986A1 (en) * 2014-06-13 2015-12-17 Genentech, Inc. Methods of treating and preventing cancer drug resistance
CZ2015250A3 (cs) * 2015-04-14 2016-10-26 Zentiva, K.S. Amorfní formy vemurafenibu
BR112017025045A2 (pt) * 2015-05-22 2018-08-07 Plexxikon Inc plx-8394 ou plx-7904 para uso no tratamento de doenças relacionadas a braf-v600
TWI804919B (zh) * 2015-06-30 2023-06-11 美商建南德克公司 含藥物之立即釋放錠劑及形成該錠劑的方法
BR112018008882A8 (pt) 2015-11-03 2019-02-26 Univ Texas método para tratar um distúrbio proliferativo e produto farmacêutico
WO2017087851A1 (en) * 2015-11-19 2017-05-26 Genentech, Inc. Methods of treating cancer using b-raf inhibitors and immune checkpoint inhibitors
WO2017095826A1 (en) * 2015-11-30 2017-06-08 The Regents Of The University Of California Combination therapy for treatment of melanoma
CN109689102A (zh) 2016-08-12 2019-04-26 基因泰克公司 Mek抑制剂,pd-1轴抑制剂,和vegf抑制剂的组合疗法
WO2018064299A1 (en) 2016-09-29 2018-04-05 Genentech, Inc. Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a taxane
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
HUE064898T2 (hu) 2017-03-02 2024-04-28 Genentech Inc HER2-pozitív emlõrák adjuváns kezelése
WO2019139970A1 (en) * 2018-01-09 2019-07-18 Duke University Topical administration of mek inhibiting agents for the treatment of skin disorders
CN109879855B (zh) * 2019-03-26 2021-01-05 中国医学科学院医药生物技术研究所 靶向肿瘤细胞表面pd-l1分子的抑制剂及其应用
WO2021229439A1 (en) * 2020-05-12 2021-11-18 Novartis Ag Therapeutic combinations comprising a craf inhibitor
CN117940130A (zh) 2021-03-09 2024-04-26 基因泰克公司 用于脑癌治疗的贝伐拉非尼
CN117561062A (zh) 2021-04-06 2024-02-13 基因泰克公司 使用贝伐拉非尼和考比替尼或使用贝伐拉非尼、考比替尼和阿特珠单抗的组合疗法
WO2023220067A1 (en) * 2022-05-09 2023-11-16 Yale University Immunotherapy of skin cancer using mpla-loaded hpg nanoparticles
WO2025008650A1 (en) * 2023-07-03 2025-01-09 Országos Onkológiai Intézet Cse inhibitor for use in the treatment of a tumor in combination with a mapk inhibitor

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002365899B2 (en) 2001-12-04 2007-09-13 Onyx Pharmaceuticals, Inc. RAF-MEK-ERK pathway inhibitors to treat cancer
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
WO2005047542A1 (en) 2003-10-16 2005-05-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatments for inhibiting development and progression of nevi and melanoma having braf mutations
KR101190912B1 (ko) 2003-11-19 2012-10-12 어레이 바이오파마 인크. Mek의 헤테로시클릭 억제제 및 그의 사용 방법
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
JP5138938B2 (ja) 2003-12-19 2013-02-06 プレキシコン インコーポレーテッド Ret調節剤の開発のための化合物および方法
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
US20060216288A1 (en) 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
MY153898A (en) 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
SI1913157T2 (sl) 2005-06-28 2017-02-28 Genentech, Inc. EGFR in KRAS mutacije za napoved bolnikovega odziva na zdravljenje z EGFR inhibitorjem
US9095581B2 (en) 2005-07-21 2015-08-04 Ardea Biosciences, Inc. Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
WO2007013997A2 (en) 2005-07-22 2007-02-01 H. Lee Moffitt Cancer Center And Research Institute Inhibition of the raf/mek/p-erk pathway for treating cancer
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
PL2073810T3 (pl) * 2006-09-13 2012-01-31 Takeda Pharmaceuticals Co Zastosowanie 2-6-(3-amino-piperydyn-1-ylo)-3-metylo-2,4-diokso-3,4-dihydro-2H-pirymidyn-1-ylometylo-4-fluoro-benzonitrylu do leczenia cukrzycy, raka, zaburzeń autoimmunizacyjnych i zakażeń HIV
EP2074226A2 (en) 2006-09-19 2009-07-01 Novartis AG Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
WO2008076415A1 (en) 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
PL2412828T3 (pl) 2007-03-13 2013-11-29 Amgen Inc Mutacje K-ras i B-raf i terapia przeciwciałami anty-EGFr
WO2008120004A1 (en) 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
CA2694646C (en) 2007-07-30 2017-09-05 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
AR072657A1 (es) 2008-02-29 2010-09-15 Genentech Inc Compuestos inhibidores de raf y metodos para su uso
WO2009111278A2 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
CA2716947A1 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
US20110003859A1 (en) 2008-02-29 2011-01-06 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
DE102008059206A1 (de) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
CA2738573C (en) 2009-04-03 2013-02-19 F. Hoffmann-La Roche Ag Compositions of propane-1 sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and uses thereof
CN102859355B (zh) 2009-08-24 2015-10-07 基因泰克公司 通过检测kras突变和rtk表达水平来测定细胞对b-raf抑制剂治疗的敏感性
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
EP2488184A4 (en) 2009-10-12 2013-04-24 Glaxosmithkline Llc COMBINATION
AU2010314287A1 (en) * 2009-10-12 2012-05-03 F. Hoffmann-La Roche Ag Combinations of a PI3K inhibitor and a MEK inhibitor
WO2011104694A2 (en) 2010-02-26 2011-09-01 GAMMAGENETICS Sàrl Detection of braf v600e mutation by allele specific real time quantitative pcr (as-qpcr) using locked nucleic acids primers and beacon probes
EP2545187B1 (en) 2010-03-09 2018-09-05 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US20120045433A1 (en) 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
WO2012027716A1 (en) 2010-08-27 2012-03-01 Collabrx, Inc. Method to treat melanoma in braf inhibitor-resistant subjects
CN103370064A (zh) * 2010-09-03 2013-10-23 百时美施贵宝公司 使用水溶性抗氧化剂的药物制剂
WO2012061683A2 (en) 2010-11-05 2012-05-10 Glaxosmithkline Llc Methods for treating cancer
WO2012068562A2 (en) 2010-11-19 2012-05-24 The Regents Of The University Of California Compositions and methods for detection and treatment of b-raf inhibitor-resistant melanomas
CN104689318A (zh) 2010-11-19 2015-06-10 葛兰素史密斯克莱知识产权(第2号)有限公司 使用braf抑制剂的治疗方法
US9295669B2 (en) * 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產(第二)有限公司 新穎醫藥組成物
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
WO2012145503A1 (en) 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
US20130172375A1 (en) 2011-12-13 2013-07-04 Hoffmann-La Roche Inc. Pharmaceutical composition
US9216170B2 (en) 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
DK2884979T3 (da) * 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
WO2014128235A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance

Similar Documents

Publication Publication Date Title
US12354130B2 (en) Combination therapies
Gutkind et al. Inhibition of mTOR signaling and clinical activity of metformin in oral premalignant lesions
Kleer et al. Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression
Luke et al. Randomized phase II trial and tumor mutational spectrum analysis from cabozantinib versus chemotherapy in metastatic uveal melanoma (Alliance A091201)
Minor et al. Sunitinib therapy for melanoma patients with KIT mutations
Ibrahim et al. Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor–positive locally advanced or metastatic breast cancer
JP6675300B2 (ja) 抗egfr薬を用いた胃癌の処置のための、egfrバイオマーカーの使用
Yuan et al. Increased expression of FAT10 is correlated with progression and prognosis of human glioma
EP4340842B1 (en) Sotorasib for use in the treatment of cancer
WO2012103060A1 (en) Method of administration and treatment
Tsushima et al. Targeted next-generation sequencing of Japanese patients with sinonasal mucosal melanomas identifies frequent NRAS and CTNNB1 mutations
WO2008009927A1 (en) Use of fulvestrant and an aromatase inhibitor for treating breast cancer
Ditsch et al. Preventive measures for patients with an elevated genetic risk for gynecological malignancies, in particular familial breast and ovarian cancer
HK40013180A (en) Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
Grisham et al. Phase II clinical trial of nirogacestat in patients with relapsed ovarian granulosa cell tumours
AUBIN et al. PERSONNEL ROSTER
Trial Efficacy of Imatinib in Aggressive Fibromatosis: Results of
Zedenius et al. 15 Pathogenesis of Thyroid Cancer
WO2010015535A1 (en) Predictive marker for egfr inhibitor treatment